Literature DB >> 23221732

Significance of the absolute number and ratio of metastatic lymph nodes in predicting postoperative survival for the International Federation of Gynecology and Obstetrics stage IA2 to IIA cervical cancer.

Ying Chen1, Lei Zhang, Jing Tian, Xin Fu, Xiubao Ren, Quan Hao.   

Abstract

PURPOSE: This study aimed to evaluate the ratio of metastatic and removed lymph nodes (RPL) and the number of metastatic lymph nodes (MLNs) in predicting postoperative survival for International Federation of Gynecology and Obstetrics stage IA2 to IIA cervical cancer after radical hysterectomy and pelvic lymphadenectomy (RHPL).
METHODS: A retrospective study was conducted in which 120 patients with lymph node metastasis who underwent RHPL for cervical cancer from 2000 to 2006 was analyzed to identify the prognostic indicators by using Kaplan-Meier and Cox proportional hazard methods.
RESULTS: Of 588 patients with cervical cancer who underwent RHPL, the 5-year survival rate (YSR) of 120 with lymph node metastasis was much lower than that of 468 without lymph node metastasis (22.4% vs 84.4%, P < 0.001). By cut-point survival analysis, RPL cutoff was designed as 10%, with the 5-YSR of 42.9% and 11.8%, and MLN count cutoffs were designed as 1 and 5, with the 5-YSR of 62.5%, 20.8%, and 7.8%, respectively. With univariate analysis, increasing RPL and MLN counts were associated with a poorer survival in women with node metastasis cervical cancers. Stage, histologic grade, RPL, and MLN count were significant independent prognostic factors for survival in a multivariate Cox proportional hazard model. In addition, RPL was verified superior to MLN count in prognostic evaluation for patients with IA2 to IIA cervical cancer after RHPL because the hazard ratio of RPL (3.195) was higher than that of MLN count (1.578).
CONCLUSIONS: The RPL and MLN count may be used as the independent prognostic parameters in patients with cervical cancer with lymph node metastasis after RHPL. Comparison of the superiority of RPL and MLN count for better predicting the survival of patients with cervical cancer deserves to be investigated further.

Entities:  

Mesh:

Year:  2013        PMID: 23221732     DOI: 10.1097/IGC.0b013e3182778bcf

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  18 in total

1.  Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer.

Authors:  Nicole D Fleming; Michael Frumovitz; Kathleen M Schmeler; Ricardo dos Reis; Mark F Munsell; Patricia J Eifel; Pamela T Soliman; Alpa M Nick; Shannon N Westin; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2014-11-18       Impact factor: 5.482

2.  Risk Stratification Based on Metastatic Pelvic Lymph Node Status in Stage IIIC1p Cervical Cancer.

Authors:  Anyang Li; Luhui Wang; Qi Jiang; Wenlie Wu; Baoyou Huang; Haiyan Zhu
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.989

3.  Lymph node ratio may predict the benefit of postoperative radiotherapy in node-positive cervical cancer.

Authors:  Juan Zhou; Qiong-Hua Chen; San-Gang Wu; Zhen-Yu He; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Ke-Li You
Journal:  Oncotarget       Date:  2016-05-17

4.  Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.

Authors:  Ali Ayhan; Nazlı Topfedaisi Ozkan; Mustafa Erkan Sarı; Husnu Celik; Murat Dede; Özgür Akbayır; Kemal Güngördük; Hanifi Şahin; Ali Haberal; Tayfun Güngör; Macit Arvas; Mehmet Mutlu Meydanlı
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

5.  The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04).

Authors:  Jeanny Kwon; Keun-Young Eom; Young Seok Kim; Won Park; Mison Chun; Jihae Lee; Yong Bae Kim; Won Sup Yoon; Jin Hee Kim; Jin Hwa Choi; Sei Kyung Chang; Bae Kwon Jeong; Seok Ho Lee; Jihye Cha
Journal:  Cancer Res Treat       Date:  2017-10-24       Impact factor: 4.679

6.  Central Pathology Review in SENTIX, A Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2).

Authors:  Kristyna Nemejcova; Roman Kocian; Christhardt Kohler; Jiri Jarkovsky; Jaroslav Klat; Alberto Berjon; Radovan Pilka; Borek Sehnal; Blanca Gil-Ibanez; Ezequiel Lupo; Almerinda Petiz; Octavio Arencibia Sanchez; Peter Kascak; Fabio Martinelli; Alessandro Buda; Jiri Presl; Marc Barahona; Luc van Lonkhuijzen; Wiktor Szatkowski; Lubos Minar; Maja Pakiz; Pavel Havelka; Cristina Zorrero; Marcin Misiek; Leon Cornelius Snyman; Dariusz Wydra; Ignace Vergote; Alla Vinnytska; Mikulas Redecha; Martin Michal; Solveig Tingulstad; Barbara Kipp; Grzegorz Szewczyk; Robert Toth; Francisco Javier de Santiago Garcia; Pluvio Jesus Coronado Martin; Robert Poka; Karl Tamussino; Mathieu Luyckx; Maxime Fastrez; Juan Carlos Staringer; Anna Germanova; Andrea Plaikner; Sylva Bajsova; Pavel Dundr; Nina Mallmann-Gottschalk; David Cibula
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

7.  TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer.

Authors:  J Wang; J Ou; Y Guo; T Dai; X Li; J Liu; M Xia; L Liu; M He
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640

8.  Prognostic significance of metastatic lymph node ratio in squamous cell carcinoma of the cervix.

Authors:  Chen Li; Wenhui Liu; Yufeng Cheng
Journal:  Onco Targets Ther       Date:  2016-06-23       Impact factor: 4.147

9.  Prognostic value of lymph node ratio in patients with small-cell carcinoma of the cervix based on data from a large national registry.

Authors:  Juan Zhou; Jia-Yuan Sun; Shan-Yu Chen; Feng-Yan Li; Huan-Xin Lin; San-Gang Wu; Zhen-Yu He
Journal:  Onco Targets Ther       Date:  2015-12-23       Impact factor: 4.147

10.  The prognostic value of negative lymph node count for patients with cervical cancer after radical surgery.

Authors:  Hao Lu; Rong Guo; Haotian Yang; Haolu Wang; Xiaowen Liang; Zhiqian Hu; Xinxing Li
Journal:  Oncotarget       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.